Title : An evaluation of selexipag for the treatment of pulmonary hypertension.

Pub. Date : 2021 Jan

PMID : 32867545






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 INTRODUCTION: Selexipag is a first-in-class, oral, long-acting, selective, non-prostanoid agonist of the prostacyclin receptor (IP receptor), indicated for the treatment of symptomatic adult pulmonary arterial hypertension (PAH). selexipag prostaglandin I2 receptor Homo sapiens